Topic · page 21 of 119

Type 2 & other diabetes

Type 2 diabetes and prediabetes: prevention, remission, glucose-lowering drugs, weight-based treatment, insulin, lifestyle and diet; monogenic and other specific types of diabetes

Briefs 801–840 of 4,758 placed here, newest publication first

Briefs in Type 2 & other diabetes

Newest publication first

Diabet Med12 Feb 2026
Chronic kidney disease in type 2 diabetes in UK primary care: Testing frequency, coding accuracy and clinical inertia
Cross-sectional study
Endocr Pract12 Feb 2026
Endocrine Care During Transition in Emerging Adults With Cystic Fibrosis: A Single Center Retrospective Study
Cohort study
Diabetes Obes Metab12 Feb 2026
Real‐world effectiveness and safety of tirzepatide in Japanese patients with type 2 diabetes: A multi‐site retrospective study
Cohort study
Cardiovasc Diabetol12 Feb 2026
Timing-dependent anti-inflammatory effects of empagliflozin in monocyte-derived macrophages from post-myocardial infarct patients with type 2 diabetes
Mechanistic study
Endocr Pract12 Feb 2026
Long-term Risk of Prediabetes and Type 2 Diabetes Following SARS-CoV-2 Infection: A Nationwide Cohort Study
Cohort study
Diabetes Res Clin Pract12 Feb 2026
Optimising lipid monitoring interval for primary prevention of cardiovascular disease in patients with type-2 diabetes: A target trial emulation study
Research article
BMJ Open Diabetes Res Care11 Feb 2026
Feasibility and cost-effectiveness of at-home self-sampling screening for type 2 diabetes: a pilot screening study in Denmark
Research article
Diabetes Metab11 Feb 2026
Glucagon-like peptide-1 receptor agonists and the risk of nonarteritic anterior ischemic optic neuropathy: Evidence from a global real-world cohort
Cohort study
J Clin Endocrinol Metab11 Feb 2026
Severity of MASH activity by iron-corrected MRI predicts insulin resistance and cardiometabolic risk in type 2 diabetes
Cross-sectional study
Diabetologia10 Feb 2026
Association of corneal nerve parameters with nerve abnormalities and neuropathic pain in prediabetes and type 2 diabetes: the Maastricht Study
Cross-sectional study
J Clin Endocrinol Metab10 Feb 2026
GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes
Cohort study
Diabet Med9 Feb 2026
Banting memorial lecture 2025: Aligning clinical practice, policy and research
Research article
Diabet Med9 Feb 2026
Post‐authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population
Cohort study
Diabetes Obes Metab9 Feb 2026
Oxidised lipoproteins and the risk of type 2 diabetes mellitus: A 5‐year cohort study on β‐cell dysfunction and prediabetes progression
Cohort study
Diabetes Obes Metab9 Feb 2026
Effects of coaching with data management system intervention or usual care on glycemic control in patients with type 2 diabetes: A multicentre, randomised controlled trial
Randomized controlled trial
Diabetes Obes Metab9 Feb 2026
Effectiveness of behavioural economics‐based financial incentives and social feedback on glycaemic control and physical activity in adults with newly diagnosed type 2 diabetes: A randomised control trial
Randomized controlled trial
Diabetes Obes Metab9 Feb 2026
Safety, feasibility, and dose‐dependent metabolic effects of endoscopic duodenal pulsed electric field therapy in adults with type 2 diabetes: Results from two multicentre proof‐of‐concept studies
Cohort study
BMJ Open Diabetes Res Care9 Feb 2026
Enhancing evidence-based care using trial emulation in electronic health records: real-world effects of empagliflozin in people with type 2 diabetes
Randomized controlled trial
Diabet Med9 Feb 2026
Targeting inflammation in cardiometabolic disease: Icosapent ethyl modulates monocyte‐derived macrophages isolated from patients with cardiovascular disease with or without type 2 diabetes
Randomized controlled trial
J Clin Endocrinol Metab8 Feb 2026
Impaired arginine, citrulline, and glutamine metabolism in type 2 diabetes: insights from a stable isotope study
Mechanistic study
Diabet Med8 Feb 2026
Type 2 diabetes in Norway 2009–2021: Have declining incidence rates continued?
Cohort study
Diabetes Res Clin Pract7 Feb 2026
SGLT2 inhibitors improve subclinical left ventricular systolic function independent of body mass index in patients with type 2 diabetes: A prospective strain imaging study
Cohort study
Diabetes Care6 Feb 2026
Pathophysiological Risk Factors Preceding Incidence of Type 2 Diabetes Subtypes: A Pooled Cohort Study in the United States
Cohort study
Diabetes Obes Metab6 Feb 2026
Transportation noise exposure and incident type 2 diabetes: A retrospective cohort study in a large U.S. healthcare system
Cohort study
Diabetes Care4 Feb 2026
Plasma Metabolite Associations for Risk and Laboratory Measures of Type 2 Diabetes in a Large-Scale Finnish Prospective Cohort
Cohort study
Diabetes Res Clin Pract4 Feb 2026
Distal symmetrical polyneuropathy in prediabetes is associated with abdominal obesity and insulin resistance
Cross-sectional study
Diabetes Obes Metab3 Feb 2026
Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy ( EFFORT ): A 24‐week, randomized, open‐label, multicenter trial
Randomized controlled trial
Diabetes Res Clin Pract3 Feb 2026
Leisure-time physical activity and sedentary behavior trajectories during middle and late adulthood in relation to type 2 diabetes mellitus: An 11-year longitudinal study
Cohort study
Diabetes Obes Metab3 Feb 2026
Physical activity and meal timing alignment with chronotype and their associations with glucose metabolism: The Maastricht Study
Cross-sectional study
Diabetes Obes Metab3 Feb 2026
Prevalence and predictors of residual gastric content in patients with type 2 diabetes on GLP ‐1 receptor agonists: A prospective observational study
Cohort study
Endocr Pract2 Feb 2026
Lower Extremity Complications in Adults With Type 2 Diabetes Treated With Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas: An Emulated Target Trial
Research article
Diabetes Care2 Feb 2026
Estimated Optimal Individualized Diabetes Risk Prediction From Preventive Interventions in the U.S. General Population
Cross-sectional study
Diabetes Obes Metab2 Feb 2026
Rationale and design of a parallel randomised trial of a plant‐based intensive lifestyle intervention for diabetes remission: The REmission of diabetes using a PlAnt ‐based weight loss InteRvention ( REPAIR ) trial
Trial design
Diabetes Obes Metab2 Feb 2026
Associations of adipose tissue insulin resistance with fasting blood glucose and HbA1c in adults without diabetes
Cross-sectional study
Diabetes Obes Metab2 Feb 2026
Synergistic effects of hypertension and diabetes on cardiovascular risk in elderly: Comparative longitudinal analysis of CHARLS and HRS
Cohort study
Obesity (Silver Spring)2 Feb 2026
Dapagliflozin‐Associated Reduction in Liver Fat Is Independent of Weight Loss in Patients With Type 2 Diabetes
Secondary analysis
Diabetes Obes Metab2 Feb 2026
Early detection of type 2 diabetes mellitus‐associated cognitive dysfunction: The potential of amide proton transfer‐weighted imaging
Diagnostic or prognostic study
JAMA Netw Open2 Feb 2026
Pancreatic Cystic Neoplasm Risk Among Individuals With Diabetes
Cohort study
JAMA Netw Open2 Feb 2026
Pediatric Diabetes Prevalence Among Medicaid Beneficiaries
Cross-sectional study
JAMA Netw Open2 Feb 2026
Pharmacist Intervention for Safer Prescribing in Patients With Type 2 Diabetes at High Risk: A Randomized Clinical Trial
Randomized controlled trial

All 4,758 Briefs in ExploreShowing Briefs 801–840 of 4,758, newest first